The Handoff: Your Week in Rheumatology News – 3/24/17
New guidelines for rheumatoid arthritis treatment with DMARDs and money being steered into lupus research highlight this week’s The Handoff.
New guidelines for rheumatoid arthritis treatment with DMARDs and money being steered into lupus research highlight this week’s The Handoff.
An observational cohort study of 4961 women with completed pregnancies and a recorded diagnosis of systemic inflammatory conditions.
Data from a population-based case control study found that systemic glucocorticoid use was associated with increased risk of S. aureus bacteremia (CA-SAB), with a clear dose-response relationship.
Recent glucocorticoid use contributed most to the current risk of diabetes, while doses taken more than 6 months previously did not.
A multidisciplinary EULAR task force reviewed the literature on dose-dependent risks related to glucocorticoid therapy in the management of chronic inflammatory rheumatic disease.
The FDA is reporting a shortage in certain presentations of Solu-Medrol Powder for Injection (Pfizer) and the generic Methylprednisolone sodium succinate for injection (Fresenius Kabi).
This is the first randomized placebo-controlled trial to demonstrate the induction and remission efficacy of IL-6 inhibition with tocilizumab in patients with giant cell arteritis (GCA).
This study found that patients receiving intraarticular (IA) hip injections within 12 weeks of elective total hip arthroplasty (THA) are at increased risk of periprosthetic joint infection (PJI).